相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models
Jing Han et al.
FASEB JOURNAL (2019)
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen et al.
NATURE REVIEWS ENDOCRINOLOGY (2019)
Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities
Jing Han et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
Michelle Beaton et al.
DIABETES (2018)
Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity
Jing Han et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations
Andreas Evers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs
Jing Han et al.
MOLECULAR PHARMACEUTICS (2018)
Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents
Jing Han et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Andreas Evers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential
Jing Han et al.
BIOCHEMICAL PHARMACOLOGY (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity
Lidan Sun et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschoep et al.
CELL METABOLISM (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?
D. Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
Vikas K. Bhat et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Peptide lipidation stabilizes structure to enhance biological function
Brian P. Ward et al.
MOLECULAR METABOLISM (2013)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1
James T. Patterson et al.
ACS CHEMICAL BIOLOGY (2011)
(D-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
Barry D. Kerr et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The metabolic actions of glucagon revisited
Kirk M. Habegger et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
分享论文
